Editas' sickle cell CRISPR therapy shows early promise, but can it stand out against Vertex? (fiercebiotech.com) en
Editas Medicine has shared early clinical data on the cell therapy it is developing to challenge Vertex and CRISPR Therapeutics for the sickle cell market. The CRISPR-edited therapy showed clear signs of efficacy but, with its rivals awaiting FDA approval, differentiating a late-to-market challenger could be tough.
